Sanofi

Sanofi-aventis

Institut National De La Sante Et De La Recherche Medicale

Eli Lilly and Company

Adir Et Compagnie

Université Louis Pasteur

Societe Civile Bioprojet

Lilly, Sa

Biocortech

Societe Civile Brioprojet

Camille-Georges Wermuth

Paola Ciapetti

Pierre Casellas

Samir Jegham

Bernard Bourrie

Kathleen Biziere

Yvette Muneaux

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Jean-Jacques Bourguignon

Pierre Sokoloff

Jean-Paul Kan

Fabrice Garrido

Concepcion Pedregal Tercero

Darryle D Schoepp

Jesus Ezquerra Carrera

Jean-Marie Derocq

Jean-Pierre Chambon

Almudena Rubio Esteban

Jean-Marie Deroco

Pierre Renard

Gerard Adam

Michelle Devissaguet

Catherine Thollon

Bruno Giros

Dinah Weissmann

Didier Rognan

Alain Lombet

Jean-François Pujol

Marie-Pascale Martres

Laurence Nathalie Deyon

De La Renaud

Jean-Francois R De La Faverie

Isabelle Morin

Andr E Mann

Ang Ele Schoenfelder

Laurence Deyon

The disclosure relates to compounds of formula (I): wherein R, R, R, R, are Rare as defined in the disclosure; their preparation method, compositions containing the same and therapeutic use thereof.

6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof

The present disclosure relates to pyridoindolone derivatives of general formula (I): to processes for preparing the same and to their use in therapeutics.

Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics

Compounds of formula: and pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R, R, R, R, and R, have the meanings given in the description; pharmaceutical compositions comprising said compounds; and processes for preparing said compounds and methods of use thereof.

6-substituted pyridoindolone derivatives, production and therapeutic use thereof

The present invention relates to pyridoindolone derivatives substituted in the 3-position by a phenyl of general formula (I): to processes for preparing the same and to their use in therapeutics.

The invention relates to novel derivatives of 14,15-dihydro 20,21-dinoreburnamenin-14-ol, having formula (I) in which R represents a radical &#x2014;AR' wherein A represents a heteroatom and R&#x2032; represents a group selected from the group comprising linear or branched C-Calkyl radicals, C-Calkenyls, C-Calkynyls, arylalkyls; esters comprising the formula &#x2014;R&#x2014; CO&#x2014;O&#x2014;R; amides comprising the formula &#x2014;R&#x2014;CO&#x2014;NZY, wherein Y and Z together can form a cycloalkyl radical or a heterocyclic radical, optionally substituted by one or more alkyl radicals; a radical selected from the group comprising alkyl radicals, alkenyls or alkynyls, substituted by at least one amine with formula &#x2014;NZY; or one of the pharmaceutically-acceptable salts thereof, including the isomers, enantiomers and diastereoisomers thereof and mixtures thereof. The invention also relates to the use of the novel derivatives for the preparation of a pharmaceutical composition which is intended, in particular, for the treatment and/or prevention of depression, sleep-wake cycle disorders and symptomatic frontal disorders in cognitive components among humans.

Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol and applications thereof

The invention relates to 2-naphthamide derivatives, in the form of bases or of salts, corresponding to the following general formula (I): ##STR1## in which: the Z-Y entity represents an N--CH.sub.2, C.dbd.CH or CH--CH.sub.2 group;

2-naphthamide derivatives and their therapeutic applications

The invention related to 2-naphthamide derivatives, in the form of bases or of salts, corresponding to the following general formula (I): ##STR1## in which: the Z--Y entity represents an N--CH.sub.2, C.dbd.CH or CH--CH.sub.2 group;

2-Naphthamide derivatives and their therapeutic applications

Disclosed herein is a method of treating a disease of the central nervous system with a compound of the formula ##STR1## in which m is 0, 1 or 2, n and q are each 0 or 1 to 5, and p is 0 or 1, X is --CO.sub.2 H or tetrazolyl,

Pharmaceutical compounds for the treatment of CNS diseases

A pharmaceutical compound of the formula ##STR1## in which m is 0, 1 or 2, n and q are each 0 or 1 to 5, and p is 0 or 1, X is --CO.sub.2 H or tetrazolyl,

Pharmaceutical compounds

The new naphthamide derivatives according to the invention are characterized in that they correspond to the general formula (I), ##STR1## where X: represents either a hydrogen atom, or a chlorine or bromine atom, or an amino or aminoalkyl group, an aminosulphamoyl group, a sulphur-containing group such as thiocyanate, alkylthio, alkylsulphinyl or alkylsulphonyl, or a methoxy group, or a nitro group, or a cyano group, or an electron-attracting group;

Naphthamide derivatives

A compound having an aryltriazine structure selected from those of formula (I): ##STR1## for which the meaning of the substituents Ar, R.sub.1, R.sub.5, R.sub.6, and R.sub.6 ' is given in the description. The compound of the invention is useful as medicinal product for disorders associated with a cholinergic dysfunction.

Compounds having an aryltriazine structure

New imidazo [1,2-c] quinazoline compounds useful as coronary smooth muscle relaxants and corresponding to the formula: ##STR1## in which: Y is oxygen or sulfur;

Imidazo [1,2-c] quinazoline compounds

The invention relates to 1,2,4-triazolo [4,3-b]pyridazines substituted in the 7-position of formula: ##STR1## in which R represents hydrogen, a lower alkyl group, a phenyl group, a chlorophenyl group or a benzyl group and R.sub.1 represents a phenyl, halogenophenyl, trifluoromethylphenyl, lower alkyl-phenyl or lower alkoxy-phenyl group or a phenyl-lower alkyl group, or one of its pharmaceutically acceptable salts. Said compounds antagonize the effects of benzodiazepines and therefore are useful as antidotes in the abuse of benzodiazepines and compounds acting on benzodiazepine receptors.

Triazolo [3,4-b]pyridazines, process for their preparation and

The invention relates to the pyridazine derivatives of the formula: ##STR1## in which R.sub.1 is H, a substituted or unsubstituted phenyl group, a naphthyl group, a cyclohexyl group, a thien-2-yl group, a thien-3-yl group or an indol-3-yl group, R.sub.2 is H or an alkyl or phenyl group, R.sub.3 is H, an alkyl, or phenyl group in formula Ib and a cyano group in formula Ia, and Alk is (CH.sub.2).sub.n where n is 2, 3 or 4, or --CH.sub.2 --C.ident.C--, and X.sup.- is halide, a process for the preparation of the said products and their application as medicaments.

Pyridazine derivatives active on the central nervous system, and

The invention relates to pyridazine derivatives substituted in the 4-position by a cyano group. It also relates to a process for the preparation of these products and their application as medicaments. ##STR1##

Pyridazine derivatives having a psychotropic action, and medicaments in

Growing community of inventors

Strasbourg, France

Camille-Georges Wermuth